Investigation on the Epidemic Prevention Effect of Using Chinese Medicine During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Outbreak.
Taipei City Hospital Linsen Chinese Medicine and Kunming Branch
Taking a regional hospital as an example, the investigators will discuss the changes in the community cumulative incidence rate(CIR) and the epidemic prevention effect of using Chinese medicine during the SARS-CoV-2 outbreak.
Main purpose:
Retrospective case study to explore the effect of traditional Chinese medicine on the prevention of SARS-CoV-2.
Secondary purpose:
If there are related side effects after taking Chinese medicine.
研究概览
详细说明
The large-scale coronavirus epidemic is a major global public health challenge in the 21st century. Since the 2003 Severe acute respiratory syndrome (SARS) epidemic spread globally and caused hundreds of deaths, the Middle East respiratory syndrome (Middle East respiratory syndrome, MERS) and coronavirus disease 2019(COVID-19) has caused a large-scale global spread and also caused a huge impact on the public health and medical system. In the country's current epidemic (Aug 1, 2021), more than 15,000 people have been diagnosed, and the number of deaths has exceeded 800. Among them, the Taipei epidemic is the most severe, and the Wanhua District of Taipei City is the hot zone. The investigators will discuss the changes in accumulation incidence rate(CIR) of the community and the epidemic prevention effect of using Chinese medicine during the SARS-CoV-2 outbreak.
This is a retrospective case study to explore the effect of traditional Chinese medicine on the prevention of SARS-CoV-2 and discuss if there are related side effects after taking Chinese medicine.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Taipei、台湾、886
- Taipei City Hospital
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- From January 1, 2020 to July 31, 2021, Chinese medicine is used for patients with new coronary pneumonia epidemic prevention.
Exclusion Criteria:
- Patients who do not use traditional Chinese medicine for the prevention of new coronary pneumonia.
- Patients who have signed and refused to provide medical records.
学习计划
研究是如何设计的？
设计细节
- 观测模型：病例对照
- 时间观点：追溯
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
JGF (Jing-Guan-Fang): Traditional Chinese Medicine Decoction
JGF group: 100ml JGF decoction per day at least 1 week
|
Use 100ml JGF decoction per day as a preventive measure for patients with COVID-19.
其他名称：
|
|
NO JGF
NO JGF group: None use traditional Chinese medicine(JGF)
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Investigation on the effect of using traditional Chinese medicine to prevent SARS-CoV-2 infection in two groups with cumulative incidence rate(CIR).
大体时间：18 months
|
Compare the dangerous states within two groups with CIR.
|
18 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.